These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 9516927)

  • 1. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
    Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
    Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice.
    Ihnat MA; Nervi AM; Anthony SP; Kaltreider RC; Warren AJ; Pesce CA; Davis SA; Lariviere JP; Hamilton JW
    Oncol Res; 1999; 11(7):303-10. PubMed ID: 10757444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues.
    Kubota T; Furukawa T; Tanino H; Oura S; Murata H; Yuasa S; Morita K; Ueno J; Kozakai R; Yano T
    Anticancer Res; 1998; 18(2A):967-72. PubMed ID: 9615748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of taxol in human head and neck tumors.
    Gan Y; Wientjes MG; Schuller DE; Au JL
    Cancer Res; 1996 May; 56(9):2086-93. PubMed ID: 8616855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.
    Bhat UG; Winter MA; Pearce HL; Beck WT
    Mol Pharmacol; 1995 Oct; 48(4):682-9. PubMed ID: 7476894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug resistance in chemotherapy for breast cancer.
    Saeki T; Tsuruo T; Sato W; Nishikawsa K
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
    Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
    Rincon M; Broadwater G; Harris L; Crocker A; Weaver D; Dressler L; Berry D; Sutton L; Michaelson R; Messino M; Kirshner J; Fleming G; Winer E; Hudis C; Appel S; Norton L; Muss H;
    Breast Cancer Res Treat; 2006 Dec; 100(3):301-8. PubMed ID: 16773437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
    Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
    Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
    Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS
    Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
    Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
    Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
    Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
    Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDR1 gene expression in primary and advanced breast cancer.
    Yang X; Uziely B; Groshen S; Lukas J; Israel V; Russell C; Dunnington G; Formenti S; Muggia F; Press MF
    Lab Invest; 1999 Mar; 79(3):271-80. PubMed ID: 10092063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.
    Yu D; Liu B; Tan M; Li J; Wang SS; Hung MC
    Oncogene; 1996 Sep; 13(6):1359-65. PubMed ID: 8808711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative and functional assay of MDR1/P170-mediated MDR in ascites cells of patients with ovarian cancer.
    Krasznai ZT; Friedländer E; Nagy A; Szabó G; Vereb G; Goda K; Hernádi Z
    Anticancer Res; 2005; 25(2A):1187-92. PubMed ID: 15868961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.